Replies to post #81075 on Biotech Values

[DewDiligence]

Copaxone vs Tysabri in the US Market

 
       Tysabri    Copaxone  
      sales ($M) sales ($M)  
 2Q09    125        438  
 1Q09    116        430  
 4Q08    115        384  
 3Q08    122        352 

The cumulative growth of US Tysabri sales during the past three quarters has been 2.5%.

The cumulative growth of US Copaxone sales during the past three quarters has been 24.4%.